Other Income & Expense
Other Charges
Kailera Therapeutics Other Charges increased by 134.1% to $5.80M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
An increase suggests unexpected non-operating costs or one-time financial hits, which can negatively impact net income.
Detailed definition
This metric captures non-operating financial expenses that do not fall under standard categories like interest or taxes....
Peer comparison
Often found in the non-operating section of the income statement; peers may label these as 'other expenses' or 'sundry charges'.
Metric ID:
hon_other_chargesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.48M | $5.80M |
| QoQ Change | — | +134.1% |
| YoY Change | — | +134.1% |
Range$2.48M – $5.80M
Avg YoY Growth+134.1%
Median YoY Growth+134.1%
Other Charges at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's other charges?
- Kailera Therapeutics (KLRA) reported other charges of $5.80M in Q1 2026.
- What does other charges mean?
- Miscellaneous non-operating financial expenses not classified elsewhere.